Jordan, Canada sign free-trade accord

The agreement will give Jordan preferential trade conditions, including full exemption from customs duties for Jordanian goods.

By
June 29, 2009 10:33

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Canada has signed a free trade-accord with Jordan, its first with an Arab country. The agreement, signed Sunday in Amman, will give Jordan preferential trade conditions, including full exemption from customs duties for Jordanian products. In return, Jordan will reduce customs duties on Canadian goods over a transitional period of four years. Forestry, manufacturing, agriculture and agri-food are expected to benefit from immediate duty-free access. The deal is expected to be ratified by both parliaments later this year. Bilateral trade stood at about $80 million in 2008, according to the Canadian Embassy in Amman, which announced the new agreement.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS